

L Number	Hits	Search Text	DB	Time stamp
1	16	primer adj1 extension near5 (different or plurality adj2 primers and tag)	USPAT; US-PGPUB; DERWENT	2003/01/30 10:30
2	150	primer adj1 extension near5 (different or plurality adj2 primers)	USPAT; US-PGPUB; DERWENT	2003/01/30 10:31
3	3	(primer adj1 extension near5 (different or plurality adj2 primers)) and repeat adj2 unit	USPAT; US-PGPUB; DERWENT	2003/01/30 10:31

Welcome to STN International! Enter x:

x

Welcome to STN International! Enter x:

LOGINID:sssptal656sxc

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Apr 08	"Ask CAS" for self-help around the clock
NEWS	3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS	4	Apr 09	ZDB will be removed from STN
NEWS	5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and
IFIUDB			
NEWS	6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and
ZCAPLUS			
NEWS	7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS	8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS	9	Jun 03	New e-mail delivery for search results now available
NEWS	10	Jun 10	MEDLINE Reload
NEWS	11	Jun 10	PCTFULL has been reloaded
NEWS	12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS	13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS	14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS	15	Jul 30	NETFIRST to be removed from STN
NEWS	16	Aug 08	CANCERLIT reload
NEWS	17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	18	Aug 08	NTIS has been reloaded and enhanced
NEWS	19	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	20	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS	21	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS	22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS	23	Sep 03	JAPIO has been reloaded and enhanced
NEWS	24	Sep 16	Experimental properties added to the REGISTRY file
NEWS	25	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS	26	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS	27	Oct 21	EVENTLINE has been reloaded
NEWS	28	Oct 24	BEILSTEIN adds new search fields
NEWS	29	Oct 24	Nutraceuticals International (NUTRACEUT) now available on
STN			
NEWS	30	Oct 25	MEDLINE SDI run of October 8, 2002
NEWS	31	Nov 18	DKILIT has been renamed APOLLIT
NEWS	32	Nov 25	More calculated properties added to REGISTRY
NEWS	33	Dec 02	TIBKAT will be removed from STN
NEWS	34	Dec 04	CSA files on STN
NEWS	35	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS	36	Dec 17	TOXCENTER enhanced with additional content
NEWS	37	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS	38	Dec 30	ISMEC no longer available
NEWS	39	Jan 13	Indexing added to some pre-1967 records in CA/CAPLUS
NEWS	40	Jan 21	NUTRACEUT offering one free connect hour in February 2003

NEWS 41 Jan 21 PHARMAML offering one free connect hour in February 2003
NEWS 42 Jan 29 Simultaneous left and right truncation added to COMPENDEX,
ENERGY, INSPEC

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,
CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:09:43 ON 30 JAN 2003

=> FIL BIOSIS MEDLINE EMBASE LIFESCI CAPLUS
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'BIOSIS' ENTERED AT 11:09:58 ON 30 JAN 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'MEDLINE' ENTERED AT 11:09:58 ON 30 JAN 2003

FILE 'EMBASE' ENTERED AT 11:09:58 ON 30 JAN 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'LIFESCI' ENTERED AT 11:09:58 ON 30 JAN 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'CAPLUS' ENTERED AT 11:09:58 ON 30 JAN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> primer (2a) extension (P) sequence(2a) tag (s) primers
PRIMER IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s primer (2a) extension (P) sequence(2a) tag (s) primers
L1 5 PRIMER (2A) EXTENSION (P) SEQUENCE(2A) TAG (S) PRIMERS

=> dup rem l1
PROCESSING COMPLETED FOR L1
L2 5 DUP REM L1 (0 DUPLICATES REMOVED)

=> d l1 1-5

L1 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS
AN 2002:638197 CAPLUS
DN 137:180749
TI Detection of genetic polymorphisms using generic molecular beacon probes
labeled with fluoresce dye-conjugated metallic or semiconductor
nanoparticles
IN Phillips, Vince; Watson, Andrew R.; Wong, Edith
PA USA
SO U.S. Pat. Appl. Publ., 27 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 2002115082	A1	20020822	US 2001-945379	20010831
PRAI	US 2000-230186P	P	20000901		

L1 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2003 ACS
AN 2001:816979 CAPLUS
DN 135:353731
TI Methods and compositions for polynucleotide analysis using generic
capture
sequences
IN Lai, Jennifer H.; Phillips, Vince E.; Watson, Andrew R.
PA Quantum Dot Corporation, USA
SO PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2001083823	A1	20011108	WO 2001-US13979	20010430
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,				
	HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,				
	LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,				
	RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,				
	VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2000-200635P	P	20000428		

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS
AN 2001:300909 CAPLUS
DN 134:321563
TI Allele detection using primer extension with sequence-coded identity tags
IN Huang, Xiaohua; Ryder, Tom; Kaplan, Paul
PA Affymetrix, Inc., USA
SO PCT Int. Appl., 42 pp.

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001029260	A2	20010426	WO 2000-US28284	20001013
	WO 2001029260	A3	20020117		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 6287778	B1	20010911	US 1999-420805	19991019
	US 2002025532	A1	20020228	US 2001-948756	20010910
PRAI	US 1999-420805	A1	19991019		

L1 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS
AN 2000:790664 CAPLUS
DN 133:345537
TI Amplification of nucleic acids using interlaced nesting primers for use in large-scale sequencing projects
IN Tillett, Daniel
PA Takara Shuzo Co., Ltd., Japan
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000066768	A1	20001109	WO 2000-AU391	20000501
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	EP 1181389	A1	20020227	EP 2000-918612	20000501
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	JP 2002542837	T2	20021217	JP 2000-615790	20000501
PRAI	AU 1999-87	A	19990430		
	WO 2000-AU391	W	20000501		

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS
AN 1999:633269 CAPLUS
DN 131:267933
TI A method for sequencing very long DNAs with a small set of primers that can be mutated and adapted to novel sequence information

IN Brenner, Sydney
PA Lynx Therapeutics, Inc., USA
SO U.S., 28 pp., Cont.-in-part of U.S. 5,780,231.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5962228	A	19991005	US 1997-916120	19970822
	US 5763175	A	19980609	US 1995-560313	19951117
	US 5780231	A	19980714	US 1996-611155	19960305
	JP 11151092	A2	19990608	JP 1998-237840	19980824
PRAI	US 1995-560313		19951117		
	US 1996-611155		19960305		
	US 1997-916120		19970822		

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s primer (2a) extension and and hybridiz?

MISSING TERM 'AND AND'

The search profile that was entered contains a logical
operator followed immediately by another operator.

=> s primer (2a) extension and hybridiz?

L3 4062 PRIMER (2A) EXTENSION AND HYBRIDIZ?

=> s l3 and array

L4 114 L3 AND ARRAY

=> s l4 and different

L5 23 L4 AND DIFFERENT

=> dup rem l5

PROCESSING COMPLETED FOR L5

L6 12 DUP REM L5 (11 DUPLICATES REMOVED)

=> d l6 1-12

L6 ANSWER 1 OF 12 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.DUPLICATE
1

AN 2002:308639 BIOSIS

DN PREV200200308639

TI Methods for gene expression monitoring on electronic microarrays.

AU Weidenhammer, Elaine M. (1); Wang, Ling; Xu, Xiao; Heller, Michael J.;
Kahl, Brenda F.

CS (1) San diego, CA USA

ASSIGNEE: Nanogen, Inc.

PI US 6379897 April 30, 2002

SO Official Gazette of the United States Patent and Trademark Office
Patents,

(Apr. 30, 2002) Vol. 1257, No. 5, pp. No Pagination.

<http://www.uspto.gov/web/menu/patdata.html>. e-file.

ISSN: 0098-1133.

DT Patent

LA English

L6 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2003 ACS

AN 2002:946900 CAPLUS

DN 138:20450
 TI Fluorescent microsphere-based readout technology for multiplexed human
 single nucleotide polymorphism analysis and bacterial identification
 IN Casey, Warren Michael; Chen, Jingwen; Colton, Heidi M.; Taylor, David;
 Weiner, Michael Phillip
 PA USA
 SO U.S. Pat. Appl. Publ., 58 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002187470	A1	20021212	US 2000-745317	20001221
PRAI	US 2000-745317		20001221		

L6 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:632737 CAPLUS
 DN 137:180735
 TI Solid phase sequencing of double-stranded nucleic acids by **array**
hybridization and mass spectrometry
 IN Fu, Dong-Jing; Cantor, Charles R.; Koster, Hubert; Smith, Cassandra L.
 PA Boston University, USA; Sequenom, Inc.
 SO U.S., 79 pp., Cont.-in-part of U.S. Ser. No. 420,009, abandoned.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 18

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6436635	B1	20020820	US 1996-614151	19960312
	US 5795714	A	19980818	US 1993-110691	19930823
	EP 1262564	A2	20021204	EP 2002-16384	19940106
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE	US 5631134	A	19970520	US 1995-462704	19950605
	CA 2218188	AA	19961017	CA 1996-2218188	19960410
	WO 9632504	A2	19961017	WO 1996-US5136	19960410
	WO 9632504	A3	19961114		
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML				
	AU 9655446	A1	19961030	AU 1996-55446	19960410
	EP 830460	A1	19980325	EP 1996-912743	19960410
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
	JP 11503611	T2	19990330	JP 1996-531243	19960410
	AU 9891379	A1	19990114	AU 1998-91379	19981106
	AU 738203	B2	20010913		
PRAI	US 1992-972012	B2	19921106		
	US 1993-1323	B2	19930107		
	US 1993-110691	A2	19930823		
	US 1995-419994	B2	19950411		
	US 1995-420009	B2	19950411		
	AU 1994-59929	A3	19940106		
	EP 1994-906047	A3	19940106		
	US 1994-322526	A3	19941017		

US 1996-614151 A 19960312
WO 1996-US5136 W 19960410
RE.CNT 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 12 MEDLINE
AN 2002716929 MEDLINE
DN 22366777 PubMed ID: 12479262
TI Characterization of overlapping XAGE-1 transcripts encoding a cancer
testis antigen expressed in lung, breast, and other types of cancers.
AU Egland Kristi A; Kumar Vasantha; Duray Paul; Pastan Ira
CS Laboratory of Molecular Biology, National Cancer Institute, NIH,
Bethesda,
Maryland 20892-4264, USA.
SO Mol Cancer Ther, (2002 May) 1 (7) 441-50.
Journal code: 101132535. ISSN: 1535-7163.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200301
ED Entered STN: 20021218
Last Updated on STN: 20030114
Entered Medline: 20030113

L6 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2003 ACS
AN 2001:935817 CAPLUS
DN 136:65168
TI Method for detecting cytosine methylation
IN Berlin, Kurt
PA Epigenomics A.-G., Germany
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001098528	A2	20011227	WO 2001-DE2274	20010619
	WO 2001098528	A3	20021128		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	DE 10029915	A1	20020103	DE 2000-10029915	20000619
PRAI	DE 2000-10029915	A	20000619		

L6 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2003 ACS
AN 2001:300909 CAPLUS
DN 134:321563
TI Allele detection using **primer extension** with
sequence-coded identity tags
IN Huang, Xiaohua; Ryder, Tom; Kaplan, Paul
PA Affymetrix, Inc., USA
SO PCT Int. Appl., 42 pp.

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001029260	A2	20010426	WO 2000-US28284	20001013
	WO 2001029260	A3	20020117		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 6287778	B1	20010911	US 1999-420805	19991019
	US 2002025532	A1	20020228	US 2001-948756	20010910
PRAI	US 1999-420805	A1	19991019		

L6 ANSWER 7 OF 12 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.DUPLICATE
2

AN 2001:180125 BIOSIS

DN PREV200100180125

TI High-throughput methods for detection of genetic variation.

AU Kristensen, Vessela Nedelcheva (1); Kelefiotis, Dimitris; Kristensen, Tom;

Borresen-Dale, Anne-Lise

CS (1) Institute for Cancer Research, Norwegian Radium Hospital, Montebello, 0310, Oslo: nedelcheva.vessela@dnr.uio.no Norway

SO Biotechniques, (February, 2001) Vol. 30, No. 2, pp. 318-332. print.
ISSN: 0736-6205.

DT Article

LA English

SL English

L6 ANSWER 8 OF 12 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.DUPLICATE
3

AN 2001:214631 BIOSIS

DN PREV200100214631

TI Fluorescent microsphere-based readout technology for multiplexed human single nucleotide polymorphism analysis and bacterial identification.

AU Ye, Fei (1); Li, May-Sung; Taylor, J. David; Nguyen, Quan; Colton, Heidi M.; Casey, Warren M.; Wagner, Michael; Weiner, Michael P.; Chen, Jingwen

CS (1) Department of Genomic Sciences, GlaxoWellcome Research and Development, 5 Moore Drive, Research Triangle Park, NC, 27709-3398 USA
SO Human Mutation, (2001) Vol. 17, No. 4, pp. 305-316. print.
ISSN: 1059-7794.

DT Article

LA English

SL English

L6 ANSWER 9 OF 12 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.DUPLICATE
4

AN 2001:267072 BIOSIS

DN PREV200100267072

TI Integration of multiple PCR amplifications and DNA mutation analyses by using oligonucleotide microchip.

AU Tillib, Sergei V.; Strizhkov, Boris N.; Mirzabekov, Andrei D. (1)

CS (1) Biochip Technology Center, Argonne National Laboratory, 9700 South
Cass Avenue, Argonne, IL, 60439: amir@anl.gov USA
SO Analytical Biochemistry, (May 1, 2001) Vol. 292, No. 1, pp. 155-160.
print.
ISSN: 0003-2697.
DT Article
LA English
SL English

L6 ANSWER 10 OF 12 MEDLINE
AN 2000252328 MEDLINE
DN 20252328 PubMed ID: 10794354
TI Arrayed **primer extension**: solid-phase four-color DNA
resequencing and mutation detection technology.
AU Kurg A; Tonisson N; Georgiou I; Shumaker J; Tollett J; Metspalu A
CS Institute of Molecular and Cell Biology, Tartu Children's Hospital,
University of Tartu, Estonian Biocentre.
SO GENETIC TESTING, (2000) 4 (1) 1-7.
Journal code: 9802546. ISSN: 1090-6576.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200006
ED Entered STN: 20000706
Last Updated on STN: 20000706
Entered Medline: 20000626

L6 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2003 ACS
AN 1999:495415 CAPLUS
DN 131:140461
TI A method combining features of random amplified polymorphic DNA and
arrayed **primer extension** for nucleic acid analysis
IN Ulfendahl, Per Johan
PA Amersham Pharmacia Biotech AB, Swed.
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9939001	A2	19990805	WO 1999-EP918	19990202
	WO 9939001	A3	19991007		
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9930276	A1	19990816	AU 1999-30276	19990202
	EP 1051523	A2	20001115	EP 1999-911663	19990202
	R:	BE, CH, DE, DK, FR, GB, IT, LI, NL, SE			
	JP 2002501760	T2	20020122	JP 2000-529458	19990202
	US 6280954	B1	20010828	US 2000-601258	20000919
PRAI	EP 1998-300741	A	19980202		
	WO 1999-EP918	W	19990202		

L6 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2003 ACS
 AN 1998:323255 CAPLUS
 DN 129:1411
 TI High density immobilization of nucleic acids and apparatus for dispensing
 nanovolumes of liquids and formation of multielement **arrays**
 IN O'Donnell, Maryanne J.; Cantor, Charles R.; Little, Daniel P.; Koster,
 Hubert
 PA Sequenom, Inc., USA; O'Donnell, Maryanne J.; Cantor, Charles R.; Little,
 Daniel P.; Koster, Hubert
 SO PCT Int. Appl., 157 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 18

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9820020	A2	19980514	WO 1997-US20195	19971106
	WO 9820020	A3	19981022		
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	US 6024925	A	20000215	US 1997-787639	19970123
	AU 9851980	A1	19980529	AU 1998-51980	19971106
	AU 745624	B2	20020328		
	EP 937096	A2	19990825	EP 1997-946893	19971106
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	DE 19782096	T	20000323	DE 1997-19782096	19971106
	DE 29724251	U1	20000921	DE 1997-29724251	19971106
	DE 29724252	U1	20000921	DE 1997-29724252	19971106
	DE 29724250	U1	20001123	DE 1997-29724250	19971106
	DE 29724341	U1	20001221	DE 1997-29724341	19971106
	JP 2001503760	T2	20010321	JP 1998-521765	19971106
	NO 9902169	A	19990706	NO 1999-2169	19990504
	US 2001008615	A1	20010719	US 1999-371150	19990809
PRAI	US 1996-746055	A	19961106		
	US 1997-786988	A	19970123		
	US 1997-787639	A	19970123		
	US 1997-947801	A	19971008		
	DE 1997-19782096	IA	19971106		
	WO 1997-US20195	W	19971106		

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST

ENTRY
47.95

SESSION
48.16

STN INTERNATIONAL LOGOFF AT 11:20:20 ON 30 JAN 2003

25

diagnosing hereditary non-polyposis colorectal cancer if said assay is positive and said colonoscopy reveals an adenoma,

wherein said nucleic acid mutation is a nucleic acid insertion or deletion, and

wherein said assay comprises the steps of:

- (a) selecting a nucleic acid having a known wild-type sequence and having a target region comprising a repeat sequence having at most three different types of nucleotide bases selected from the group consisting of dGTP, dATP, dTTP, and dCTP;
- (b) contacting a sample with an oligonucleotide primer that is complementary to a portion of said nucleic acid immediately upstream of said target region;
- (c) extending said primer in the presence of nucleotide bases that are complementary to the nucleotide bases of the target region, thereby to form a primer extension product;
- (d) extending the primer extension product in the presence of a labeled nucleotide complementary to a nucleotide base downstream from the target region in said nucleic acid, wherein said labeled nucleotide is not complementary to any of the nucleotide bases of the target region selected in step (a), thereby to produce a labeled extension product comprising a sequence that is complementary to the entire target region;
- (e) terminating the primer extension product by incorporating a terminator nucleotide in said product that is complementary to a nucleotide downstream from the target region in a wild type nucleic acid, wherein said terminator nucleotide is not complementary to any of the nucleotides of the target region selected in step (a), said step of terminating the primer extension product being performed simultaneously with or immediately after step (d).
- (f) detecting the labeled extension product; and
- (g) comparing the size of the labeled extension product detected in step (f) to a standard, wherein a labeled

26

extension product smaller than the standard is indicative of the presence of a deletion in the target region and a labeled extension product larger than the standard is indicative of the presence of an insertion in the target region.

8. The method of claim 1, wherein the labeled nucleotide and the terminator nucleotide are the same.

9. The method of claim 1, wherein more than one labeled nucleotide is incorporated into the extension product prior to incorporation of the terminator nucleotide.

10. The method of claim 1, wherein the nucleotide bases of step (c) are unlabeled.

11. The method of claim 1, wherein the labeling reaction of step (d) is performed in the presence of labeled nucleotide and unlabeled nucleotide of the same type.

12. The method of claim 10, wherein the ratio of labeled nucleotides to unlabeled nucleotides is 1:1.6 (unlabeled:labeled).

13. The method of claim 10, wherein more than one labeled nucleotide from step (d) is incorporated into the labeled extension product.

14. The method of claim 12, wherein only one of the incorporated nucleotides is labeled.

15. The method of claim 1, wherein said biological sample contains a heterogeneous mixture of mutant nucleic acid having a deletion in the target region and wild type nucleic acid with no deletion in the target region.

16. The method of claim 1, wherein a deletion in the target region is present in from about 1% to about 5% of the nucleic acid molecules containing the target region.

17. The method of claim 1, wherein the presence of a deletion in said target region is associated with the presence of a mutation at a separate genetic locus selected from the group consisting of APC, DCC, P53, and RAS.

18. The method of claim 1, wherein said target region is the poly-A tract at the BAT-26 locus.

19. The method of claim 1, wherein said target region is a microsatellite region.

* * * * *

-continued

gttaannnnn nnnacagat agtgaagaag gcttagaaag gagctaaaag agttcgacat 300
caatattaga caag 314

What is claimed is:

1. A method for diagnosing colorectal cancer or precancer, the method comprising the steps of:

performing an assay to detect, in a stool sample from a patient, a nucleic acid mutation indicative of a colorectal lesion;

performing a sigmoidoscopy on said patient; and

diagnosing colorectal cancer or precancer in said patient if at least one of said assay step and said sigmoidoscopy step is positive,

wherein said nucleic acid mutation is a nucleic acid insertion or deletion, and

wherein said assay comprises the steps of:

(a) selecting a nucleic acid having a known wild-type sequence and having a target region comprising a repeat sequence having at most three different types of nucleotide bases selected from the group consisting of dGTP, dATP, dTTP, and dCTP;

(b) contacting a sample with an oligonucleotide primer that is complementary to a portion of said nucleic acid immediately upstream of said target region;

(c) extending said primer in the presence of nucleotide bases that are complementary to the nucleotide bases of the target region, thereby to form a primer extension product;

(d) extending the primer extension product in the presence of a labeled nucleotide complementary to a nucleotide base downstream from the target region in said nucleic acid, wherein said labeled nucleotide is not complementary to any of the nucleotide bases of the target region selected in step (a), thereby to produce a labeled extension product comprising a sequence that is complementary to the entire target region;

(e) terminating the primer extension product by incorporating a terminator nucleotide in said product that is complementary to a nucleotide downstream from the target region in a wild type nucleic acid, wherein said terminator nucleotide is not complementary to any of the nucleotides of the target region selected in step (a), said step of terminating the primer extension product being performed simultaneously with or immediately after step (d);

(f) detecting the labeled extension product; and

(g) comparing the size of the labeled extension product detected in step (f) to a standard, wherein a labeled extension product smaller than the standard is indicative of the presence of a deletion in the target region and a labeled extension product larger than the standard is indicative of the presence of an insertion in the target region.

2. The method of claim 1, wherein said assay is conducted prior to said sigmoidoscopy.

3. The method of claim 1, wherein said sigmoidoscopy is performed prior to said assay.

4. The method of claim 1, wherein said mutation is indicative of the presence of a colorectal lesion in the proximal colon.

5. The method of claim 1, wherein said sample includes a buffer comprising at least 100 mM EDTA.

6. A method for localizing a colorectal lesion in a patient, the method comprising the steps of:

performing an assay to detect, in a stool sample from a patient, a nucleic acid mutation indicative of said colorectal lesion;

performing a sigmoidoscopy on said patient;

diagnosing a proximal colonic lesion if said assay is positive for the mutation and said sigmoidoscopy is negative; and

diagnosing a distal colonic lesion if said sigmoidoscopy is positive and said assay is negative for the mutation, wherein said nucleic acid mutation is a nucleic acid insertion or deletion, and

wherein said assay comprises the steps of:

(a) selecting a nucleic acid having a known wild-type sequence and having a target region comprising a repeat sequence having at most three different types of nucleotide bases selected from the group consisting of dGTP, dATP, dTTP, and dCTP;

(b) contacting a sample with an oligonucleotide primer that is complementary to a portion of said nucleic acid immediately upstream of said target region;

(c) extending said primer in the presence of nucleotide bases that are complementary to the nucleotide bases of the target region, thereby to form a primer extension product;

(d) extending the primer extension product in the presence of a labeled nucleotide complementary to a nucleotide base downstream from the target region in said nucleic acid, wherein said labeled nucleotide is not complementary to any of the nucleotide bases of the target region selected in step (a), thereby to produce a labeled extension product comprising a sequence that is complementary to the entire target region;

(e) terminating the primer extension product by incorporating a terminator nucleotide in said product that is complementary to a nucleotide downstream from the target region in a wild type nucleic acid, wherein said terminator nucleotide is not complementary to any of the nucleotides of the target region selected in step (a), said step of terminating the primer extension product being performed simultaneously with or immediately after step (d).

(f) detecting the labeled extension product; and

(g) comparing the size of the labeled extension product detected in step (f) to a standard, wherein a labeled extension product smaller than the standard is indicative of the presence of a deletion in the target region and a labeled extension product larger than the standard is indicative of the presence of an insertion in the target region.

7. A method for diagnosing hereditary non-polyposis colorectal cancer, the method comprising the steps of:

performing an assay to detect, in a stool sample from a patient, a nucleic acid mutation indicative of said hereditary non-polyposis colorectal cancer;

performing a colonoscopy on said patient; and

centrifugation, dried, and dissolved in 20 μ l mM Tris-HCl, pH 8.0; 1 mM EDTA.

Two microliters of each sample were electrophoresed on a 1.4% agarose gel (8.3-cm \times 6 cm) in TAE buffer (40 mM Tris-acetate, pH 7.8; 5 mM sodium acetate; 1 mM EDTA) at 50 V for 160 min. After staining with ethidium, the gel was photographed using ultraviolet illumination. The results in FIG. 6 show that samples Hu1 and Hu2 have a prominent band at approximately 1.3 kb that is not present in the four other samples. Thus, amplification using the 10 nucleotide primer AP9 was able to detect a genetic polymorphism that can be used to distinguish human DNA samples.

EXAMPLE 8

Quantitation of PCR Products

In Example 3, the process of this invention was used to genetically map a polymorphism. This was accomplished by determining the parental pattern of inheritance of the polymorphism in several segregating individuals. As practiced in Example 3, the investigator is unable to distinguish individuals heterozygous for a marker from individuals homozygous for the same marker, and the polymorphism is scored as being dominant. A heterozygous individual contains two different copies (alleles) of a particular DNA segment at a position (locus) in the genome. A homozygous individual will contain two identical alleles at a locus. In several applications (e.g., quantitative trait mapping) it is necessary to be able to distinguish heterozygous individuals. In the process of the present invention, it is expected that individuals inheriting two copies of a single allele will have two times the amount of amplified product as an individual inheriting only one copy of the same allele. To investigate whether heterozygotes could be distinguished from homozygotes by quantitating the results of the assay, individuals were chosen which were known to be homozygous for Bonus, heterozygous for both Bonus and PI81762 or homozygous for PI81762 DNA segments for the chromosomal region containing the band A polymorphism. These individuals were chosen on the basis of the genotype of flanking RFLP markers (see Example 3 and Table 3). The same gels presented in Example 3 were analyzed by densitometry to determine the amount of amplified product corresponding to band A (see legend to FIG. 7). Panel A of FIG. 7 represents a scan of individual 30 (see Example 3) homozygous for the PI81762 allele. Panel B of FIG. 7 represents a scan of individual 9 (see Example 3) heterozygous for Bonus and PI81762 alleles. Panel C of FIG. 7 represents a scan of individual 57 (see Example 3) homozygous for the Bonus allele. Peaks corresponding to the band A polymorphism are labeled. The densitometry shows that individuals homozygous for PI81762 alleles contain twice the amount of DNA in the band A polymorphism than individuals which are heterozygous for PI81762 and Bonus. Individuals homozygous for the Bonus alleles do not contain any DNA corresponding to band A. This example shows that the products of amplification can be quantitated to identify heterozygous individuals and reveal a co-dominant polymorphism. This will have utility in procedures where it is necessary to distinguish heterozygotes from the corresponding homozygote.

Photographs of the gel separations shown in FIG. 2 were digitized using a Cohu Monochrome CCD camera (model #4815-5000, Cohu Inc., San Diego, Calif.) attached to a Macintosh IIfx computer (Apple Computer Corp., Cupertino, Calif.). The analog data was converted to digital input through a QuickCapture card (Data Translations Inc., Marlboro, Mass.). The individ-

ual lanes were scanned for quantitation with the Scan Analysis program (Version 2.11, Biosoft Inc., Milltown, N.J.). X-axis values correspond to electrophoretic distance, and Y-axis values correspond to peak intensity.

What is claimed is:

1. A process for detecting polymorphisms on the basis of nucleotide differences in random segments of nucleic acids comprising:

(a) separately performing an extension reaction on a random segment of each of at least two nucleic acids from different sources, said reaction comprising:

(i) contacting each of the nucleic acids with at least one nonspecifically targeted oligonucleotide primer of greater than 7 nucleotides under conditions such that for at least one nucleic acid a random extension product of at least one primer is synthesized; and

(b) comparing the results of the separately performed random extension reactions for differences.

2. The process of claim 1, after step (i) and before step (b), further comprising the additional steps of (ii) dissociating the extension product from its complement; and (iii) amplifying the random nucleic acid segment by contacting the dissociated extension product with at least one primer of step (i) under conditions such that an amplification extension product is synthesized using the dissociated extension product as a template.

3. The process of claim 2 wherein the steps are performed at least twice.

4. The process of claim 1 or 2 using a nucleic acid polymers and nucleoside triphosphate substrates or their analogues and mixtures thereof.

5. The process of claim 1 or 2 wherein one primer is employed.

6. The process of claim 1 or 2 wherein the primer is from 9 to 10 nucleotides in length.

7. The process of claim 1 or 2 wherein at least one primer is biotinylated.

8. The process of claim 1 or 2 wherein the nucleic acids are from different individual organisms.

9. A process according to claim 4, wherein the nucleic acid polymerase is a DNA polymerase and the nucleoside triphosphate substrates are deoxyribonucleoside triphosphate substrates.

10. A process according to claim 9, wherein the DNA polymerase is a thermostable polymerase.

11. A process according to claim 10, wherein the DNA polymerase is Taq polymerase.

12. The process of claim 1 or 2, wherein the comparison is through size separation of the random extension products.

13. A process according to claim 12, wherein the size separation comparison is performed by electrophoresis through a polyacrylamide gel matrix or agarose gel matrix.

14. The process of claim 1 or 2, wherein the comparison is through nucleotide sequence determination.

15. The process of claim 1 or 2, wherein the nucleic acid source is selected from the group consisting of plants, animals and microbes.

16. The process of claim 1 or 2 wherein the nucleic acid source is human.

17. The process of claim 1 or 2 wherein a difference in the random extension products is used as a marker to construct a genetic map.

18. The process of claim 1 or 2 wherein a difference in the random extension products is used as a marker to distinguish or identify individuals.

-continued

tctctctttt nntnnt

16

<210> SEQ ID NO 42
 <211> LENGTH: 14
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Labelled PNA
 <221> NAME/KEY: misc_feature
 <222> LOCATION: (9)..(13)
 <223> OTHER INFORMATION: n = pseudo-isocytosine, 5-propynyl cytidine

<400> SEQUENCE: 42

tctctctttn tnnt

14

<210> SEQ ID NO 43
 <211> LENGTH: 19
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Labelled DNA

<400> SEQUENCE: 43

cctgcaggcc cgtgcccgct

19

<210> SEQ ID NO 44
 <211> LENGTH: 28
 <212> TYPE: DNA
 <213> ORGANISM: Unknown
 <220> FEATURE:
 <223> OTHER INFORMATION: DNA

<400> SEQUENCE: 44

gcaaatataa ggtccctgac tactggta

28

<210> SEQ ID NO 45
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Unknown
 <220> FEATURE:
 <223> OTHER INFORMATION: DNA

<400> SEQUENCE: 45

gtgctgcat gccaggctact

20

We claim:

1. A binary composition for hybridizing to a target polynucleotide sequence comprising:
 - a probe comprising a target-specific portion and a clamp-specific portion wherein the target-specific portion is capable of sequence-specific binding to a target polynucleotide sequence; and
 - a clamp comprising two probe-specific portions, one or more labels and at least one nucleic acid analog selected from a nucleobase analog, a sugar analog, and an internucleotide analog;
 wherein the probe is hybridized to the clamp by sequence-specific binding of the probe-specific portion of the clamp to the clamp-specific portion of the probe, and the clamp is incapable of sequence-specific binding to the target polynucleotide; and
- wherein the two probe-specific portions are capable of sequence-specific binding to the clamp-specific portion of the probe to form a triplex.

2. The binary composition of claim 1 wherein the probe comprises 6 to 100 nucleotides.

3. The binary composition of claim 1 wherein the clamp-specific portion of the probe comprises purine nucleotides.

4. The binary composition of claim 1 wherein the probe-specific portion of the clamp comprises pyrimidine nucleobase analogs.

5. The binary composition of claim 1 wherein the clamp comprises 6 to 50 nucleic acid analogs.

6. The binary composition of claim 1 wherein the clamp sequence comprises (CAG)_n where n=1-10.

7. The binary composition of claim 1 wherein the clamp sequences include (TCC)_n and nucleic acid analogs which bind the probe sequence (GGA)_n where n=1-10.

8. The binary composition of claim 1 wherein the probe comprises a nucleic acid analog selected from the group consisting of a nucleobase analog, a sugar analog, and an internucleotide analog.

9. The binary composition of claim 8 wherein the nucleobase analog is selected from the group consisting of C-5-

-continued

```

<211> LENGTH: 69
<212> TYPE: DNA
<213> ORGANISM: Unknown Organism
<220> FEATURE:
<223> OTHER INFORMATION: Description of Unknown Organism: test sequence

<400> SEQUENCE: 5
taggtgaggc tgtggctgaa caataacggg catcattggt tgctgggctg ctgagctggc    60
accactgcc                                     69

<210> SEQ ID NO 6
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Unknown Organism
<220> FEATURE:
<223> OTHER INFORMATION: Description of Unknown Organism: test sequence

<400> SEQUENCE: 6
taggtgaggc tgtggctgaa caatgaacag gcacagtcg ttgctgggct gctgagctgg    60
caccactgcc                                     70

```

We claim:

1. A method for detecting a target polynucleotide sequence comprising the steps of:

(a) amplifying a target polynucleotide with primer extension reagents in a first set of one or more vessels and amplifying an external control polynucleotide with the primer extension reagents in a second set of one or more vessels;

wherein the primer extension reagents include a forward primer, a reverse primer, one or more detectable probes, a polymerase, and one or more nucleotide 5'-triphosphates;

the forward primer and the detectable probe are separated by 0 to 5 nucleotides when hybridized to the external control polynucleotide, or its complement, and the reverse primer and the detectable probe are separated by 0 to 5 nucleotides when hybridized to the external control polynucleotide, or its complement; and

the external control polynucleotide begins the amplification process as a single-stranded polynucleotide; and

the external control polynucleotide is shorter than the target polynucleotide; and

(b) detecting a signal from said one or more detectable probes.

2. The method of claim 1 wherein said detectable probe is a self-quenching fluorescence probe comprising a reporter dye and a quencher.

3. The method of claim 2 wherein said polymerase cleaves said self-quenching fluorescence probes during amplification to separate said reporter dye from said quencher.

4. The method of claim 1 wherein the primer extension reagent of the second set of vessels comprises a first detectable probe and a second detectable probe; the sequence of the first probe differs from the second probe by one or more mismatches, insertions, or deletions, and the signal of the first probe is resolvable from the signal of the second probe.

5. The method of claim 2 wherein the primer extension reagent of the second set of vessels comprises a first self-

quenching fluorescence probe and a second self-quenching fluorescence probe; the sequence of the first probe differs from the second probe by one or more mismatches, insertions, or deletions, and the reporter dye of the first probe is spectrally resolvable from the reporter dye of the second probe.

6. The method of claim 5 wherein the sequences of the first self-quenching fluorescence probe and second self-quenching fluorescence probe differ by a single nucleotide mismatch.

7. The method of claim 1 further comprising amplifying a second single-stranded external control polynucleotide with primer extension reagents in a third set of one or more vessels.

8. The method of claim 7 wherein the sequence of the first single-stranded external control polynucleotide differs from the second single-stranded external control polynucleotide by one or more mismatches, insertions, or deletions.

9. The method of claim 7 wherein the sequence portion of the first single-stranded external control polynucleotide complementary to a detectable probe differs by a single nucleotide from the sequence portion of the second single-stranded external control polynucleotide complementary to a detectable probe.

10. The method of claim 7 further comprising a fourth set of one or more vessels including primer extension reagents.

11. The method of claim 1 wherein the target polynucleotide is selected from the group consisting of a plasmid, a cDNA, a PCR product, genomic DNA, a restriction digest, and a ligation product.

12. The method of claim 1 wherein the forward primer or the reverse primer, and the detectable probe are adjacent when hybridized to the single-stranded external control polynucleotide, or its complement.

13. The method of claim 1 wherein the external control polynucleotide, or its complement, forms single-stranded overhangs consisting of 0 to about 10 nucleotides when hybridized to the forward primer or to the reverse primer.

14. The method of claim 1 wherein the forward primer and reverse primer are each 10 to 40 nucleotides in length.

23

15. The method of claim 2 wherein the self-quenching fluorescence probe is 10 to 40 nucleotides in length.

16. The method of claim 1 wherein the single-stranded external control polynucleotide is 30 to 110 nucleotides in length.

17. The method of claim 1 wherein the single-stranded external control polynucleotide is 50 to 70 nucleotides in length.

18. The method of claim 1 wherein a change in fluorescence intensity is detected as an indication of the presence of the target sequence.

19. The method of claim 1 wherein the products of the nucleic acid amplification of the target polynucleotide and the external control polynucleotide are detected by end-point analysis.

20. The method of claim 1 wherein the products of the nucleic acid amplification of the target polynucleotide and the external control polynucleotide are detected during real-time analysis.



21. The method of claim 1 wherein the products of the nucleic acid amplification of the target polynucleotide and the external control polynucleotide are detected by fluorescence.

22. The method of claim 1 wherein said nucleic acid polymerase is a thermostable polymerase with 5' nuclease activity.

23. The method of claim 2 wherein said reporter is a xanthene dye.





24. The method of claim 23 wherein said xanthene dye is a fluorescein dye.

25. The method of claim 24 wherein said fluorescein dye is selected from the group consisting of:



24


-continued



where X is an attached site to the probe.

26. The method of claim 2 wherein said quencher is selected from the group consisting of:

25



26

where X is an attachment site to the probe.

27. The method of claim 2 wherein said reporter dye is separated from said quencher by at least 12 nucleotides.

28. The method of claim 2 wherein said reporter dye is attached at the 5' terminus or 3' terminus of the self-quenching fluorescence probe.

29. The method of claim 2 wherein said quencher is attached at the 5' terminus or 3' terminus of the self-quenching fluorescence probe.


30. The method of claim 2 wherein said quencher is non-fluorescent.

31. The method of claim 1 wherein the detectable probe is labelled with a minor groove binder.

32. The method of claim 2 wherein the self-quenching fluorescence probe is labelled with a minor groove binder.

33. The method of claim 32 wherein the self-quenching fluorescence probe is labelled with a minor groove binder at the 3' terminal nucleotide.

34. The method of claim 32 wherein the minor groove binder has the structure:



where X is an attachment site to the probe.

35. The method of claim 1 where one or more nucleotide 5'-triphosphates are labelled.

36. The method of claim 35 wherein the label is a fluorescent dye, a quencher, biotin, or a minor groove binder.

37. The method of claim 1 wherein the vessels are located in a microwell tray.

38. The method of claim 1 wherein the primer extension reagents are delivered to the vessels by robotic means.

39. The method of claim 1 wherein amplification is conducted by a thermal cycler.

* * * * *

-continued

(A) LENGTH: 21 nucleotides
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(x i) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

CAAGCTTCCC GTTCTCAGCC T

2 1

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 30 nucleotides
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(x i) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

ACCGTCAAGG CTGAGAACGG GAAGCTTGTC

3 0

What is claimed is:

1. A method for detecting a target polynucleotide in a sample comprising:

contacting said sample of nucleic acids with an oligo-
 nucleotide probe under conditions where said oligo-
 nucleotide probe selectively hybridizes to said target
 polynucleotide, said oligonucleotide probe including a
 fluorescent reporter molecule and a quencher molecule
 capable of quenching the fluorescence of said reporter
 molecule which are attached to said oligonucleotide
 probe such that said oligonucleotide probe is capable of
 adopting at least one single-stranded conformation
 when not hybridized to said target polynucleotide
 where said quencher molecule quenches the fluores-
 cence of said reporter molecule and is capable of
 adopting at least one conformation when hybridized to
 said target polynucleotide where the fluorescence of
 said reporter molecule is unquenched such that the
 fluorescence intensity of said reporter molecule when
 said oligonucleotide probe is hybridized to said target
 polynucleotide is greater than the fluorescence intensity
 of said reporter molecule when said oligonucleotide
 probe is not hybridized to said target polynucleotide
 and said oligonucleotide probe is not hybridized with
 itself in the form of a hairpin structure; and

monitoring the fluorescence of said reporter molecule
 fluorescence intensity of said reporter molecule indi-
 cating the presence of said under conditions where said
 oligonucleotide probe does not hybridize with itself to
 form a hairpin structure in order to detect the hybrid-
 ization of said target polynucleotide to said oligonucle-
 otide probe.

2. The method according to claim 1 wherein the fluores-
 cence intensity of said reporter molecule under conditions
 where said oligonucleotide probe does not hybridize with
 itself to form a hairpin structure is at least about a factor of
 6 greater when said oligonucleotide probe is hybridized to
 said target polynucleotide than when said oligonucleotide
 probe is not hybridized to said target polynucleotide.

3. The method according to claim 1 wherein said reporter
 molecule is separated from said quencher molecule by at
 least 15 nucleotides.

4. The method according to claim 1 wherein said reporter
 molecule is separated from said quencher molecule by
 between 15 and 60 nucleotides.

5. The method according to claim 1 wherein said reporter
 molecule is separated from said quencher molecule by at
 least 18 nucleotides.

6. The method according to claim 5 wherein said reporter
 molecule is separated from said quencher molecule by
 between 18 and 30 nucleotides.

7. The method according to claim 1 wherein said reporter
 molecule is attached to a 3' terminal nucleotide of said
 oligonucleotide probe.

8. The method according to claim 7 wherein said
 quencher molecule is attached to a 5' terminal nucleotide of
 said oligonucleotide probe.

9. The method according to claim 1 wherein said reporter
 molecule is attached to a 5' terminal nucleotide of said
 oligonucleotide probe.

10. The method according to claim 9 wherein said
 quencher molecule is attached to a 3' terminal nucleotide of
 said oligonucleotide probe.

11. The method according to claim 1 wherein said
 quencher molecule is attached to a 3' terminal nucleotide of
 said oligonucleotide probe.

12. The method according to claim 1 wherein said
 quencher molecule is attached to a 5' terminal nucleotide of
 said oligonucleotide probe.

13. The method according to claim 1 wherein said
 reporter molecule is a fluorescein dye and said quencher
 molecule is a rhodamine dye.

14. The method according to claim 1 wherein said
 quencher is fluorescent and the fluorescence intensity of said
 reporter molecule is greater than the fluorescence intensity
 of said quencher molecule when said oligonucleotide probe
 is hybridized to said target polynucleotide.

15. The method according to claim 14 wherein the fluo-
 rescence intensity of said reporter molecule is at least about
 a factor of 3.5 greater than the fluorescence intensity of said
 quencher molecule when said probe is hybridized to said
 target polynucleotide.

16. A method for detecting a target polynucleotide in a
 sample comprising:

contacting said sample of nucleic acids with an oligo-
 nucleotide probe under conditions where said oligo-
 nucleotide probe selectively hybridizes to said target
 polynucleotide, said oligonucleotide probe including a
 fluorescent reporter molecule and a fluorescent
 quencher molecule capable of quenching the fluores-
 cence of said reporter molecule which are attached to
 said oligonucleotide probe such that said oligonucle-
 otide probe is capable of adopting at least one single-
 stranded conformation when not hybridized to said

25

target polynucleotide where said fluorescent quencher molecule quenches the fluorescence of said reporter molecule and is capable of adopting a least one conformation when hybridized to said target polynucleotide where the fluorescence of said reporter molecule is unquenched such that the ratio of the fluorescence intensities of said reporter molecule to said fluorescent quencher molecule when said oligonucleotide sequence is hybridized to said target polynucleotide is greater than the ratio of the fluorescence intensities of said reporter molecule to said fluorescent quencher molecule when said oligonucleotide probe is not hybridized to said target polynucleotide and said oligonucleotide probe is not hybridized with itself in the form of a hairpin structure; and

monitoring the ratio between the fluorescence of said reporter molecule and said fluorescent quencher molecule under conditions where said oligonucleotide probe does not hybridize with itself to form a hairpin structure in order to detect the hybridization of said target polynucleotide to said oligonucleotide probe.

17. The method according to claim 16 wherein the ratio of the fluorescence intensities of said reporter molecule to said quencher molecule when said oligonucleotide probe is hybridized to said target polynucleotide is at least a factor of 6 greater than the ratio of the fluorescence intensities of said reporter molecule to said quencher molecule when said oligonucleotide probe is not hybridized to said target polynucleotide.

18. A method for detecting a target polynucleotide in a sample comprising:

contacting a sample of nucleic acids with an oligonucleotide probe attached to a solid support under conditions favorable for hybridization of said oligonucleotide probe to said target polynucleotide, said oligonucleotide probe including a fluorescent reporter molecule and a quencher molecule capable of quenching the fluorescence of said reporter molecule which are attached to said oligonucleotide probe such that said oligonucleotide probe is capable of adopting at least one single-stranded conformation when not hybridized to said target polynucleotide where said quencher molecule quenches the fluorescence of said reporter molecule and is capable of adopting at least one conformation when hybridized to said target polynucleotide where the fluorescence of said reporter molecule is unquenched such that the fluorescence intensity of said reporter molecule when said oligonucleotide probe is hybridized to said target polynucleotide is greater than the fluorescence intensity of said reporter molecule when said oligonucleotide probe is not hybridized to said target polynucleotide and said oligonucleotide probe is not hybridized with itself in the form of a hairpin structure; and

monitoring the fluorescence of said reporter molecule under conditions where said oligonucleotide probe does not hybridize with itself to form a hairpin structure in order to detect the hybridization of said target polynucleotide to said oligonucleotide probe.

19. The method according to claim 18 wherein the fluorescence intensity of said reporter molecule under conditions where said oligonucleotide probe does not hybridize with itself to form a hairpin structure is at least about a factor of 6 greater when said oligonucleotide probe is hybridized to said target polynucleotide than when said oligonucleotide probe is not hybridized to said target polynucleotide.

20. The method according to claim 18 wherein said reporter molecule is separated from said quencher molecule by at least 15 nucleotides.

26

21. The method according to claim 20 wherein said reporter molecule is separated from said quencher molecule by between 15 and 60 nucleotides.

22. The method according to claim 18 wherein said reporter molecule is separated from said quencher molecule by at least 18 nucleotides.

23. The method according to claim 22 wherein said reporter molecule is separated from said quencher molecule by between 18 and 30 nucleotides.

24. The method according to claim 18 wherein said reporter molecule is attached to a 3' terminal nucleotide of said oligonucleotide probe.

25. The method according to claim 24 wherein said quencher molecule is attached to a 5' terminal nucleotide of said oligonucleotide probe.

26. The method according to claim 18 wherein said reporter molecule is attached to a 5' terminal nucleotide of said oligonucleotide probe.

27. The method according to claim 26 wherein said quencher molecule is attached to a 3' terminal nucleotide of said oligonucleotide probe.

28. The method according to claim 18 wherein said quencher molecule is attached to a 3' terminal nucleotide of said oligonucleotide probe.

29. The method according to claim 18 wherein said quencher molecule is attached to a 5' terminal nucleotide of said oligonucleotide probe.

30. The method according to claim 18 wherein said reporter molecule is a fluorescein dye and said quencher molecule is a rhodamine dye.

31. The method according to claim 18 wherein said probe is attached to said solid support by a linker.

32. The method according to claim 31 wherein said linker separates said probe from said solid support by at least 30 atoms.

33. The method according to claim 32 wherein said linker separates said probe from said solid support by at least 50 atoms.

34. The method according to claim 31 wherein said linker is a functionalized polyethylene glycol.

35. The method according to claim 34 wherein said linker is a polynucleotide.

36. The method according to claim 18 wherein said quencher molecule is fluorescent and the fluorescence intensity of said reporter molecule is greater than the fluorescence intensity of said quencher molecule when said oligonucleotide probe is hybridized to said target polynucleotide.

37. The method according to claim 36 wherein the fluorescence intensity of said reporter molecule is at least about a factor of 3.5 greater than the fluorescence intensity of said quencher molecule when said probe is hybridized to said target polynucleotide.

38. A method for detecting a target polynucleotide in a sample comprising:

contacting said sample of nucleic acids with an oligonucleotide probe attached to a solid support under conditions where said oligonucleotide probe selectively hybridizes to said target polynucleotide, said oligonucleotide probe including a fluorescent reporter molecule and a fluorescent quencher molecule capable of quenching the fluorescence of said reporter molecule which are attached to said oligonucleotide probe such that said oligonucleotide probe is capable of adopting at least one single-stranded conformation when not hybridized to said target polynucleotide where said fluorescent quencher molecule quenches the fluorescence of said reporter molecule and is capable of

27

adopting at least one conformation when hybridized to said target polynucleotide where the fluorescence of said reporter molecule is unquenched such that the ratio of the fluorescence intensities of said reporter molecule to said fluorescent quencher molecule when said oligonucleotide sequence is hybridized to said target polynucleotide is greater than the ratio of the fluorescence intensities of said reporter molecule to said fluorescent quencher molecule when said oligonucleotide probe is not hybridized to said target polynucleotide and said oligonucleotide probe is not hybridized with itself in the form of a hairpin structure; and monitoring the ratio between the fluorescence of said reporter molecule and said fluorescent quencher mol-

28

ecule under conditions where said oligonucleotide probe does not hybridize with itself to form a hairpin structure in order to detect the hybridization of said target polynucleotide to said oligonucleotide probe.

39. The method according to claim 38 wherein the ratio of the fluorescence intensities of said reporter molecule to said quencher molecule when said oligonucleotide sequence is hybridized to said target polynucleotide is at least a factor of 6 greater than the ratio of the fluorescence intensities of said reporter molecule to said quencher molecule when said oligonucleotide sequence is not hybridized to said target polynucleotide.

* * * * *

C) Piperidine Cleavage

Chemical cleavage of the C and T bases that react with hydroxylamine or osmium tetroxide is achieved by incubating the dishes with 1M piperidine at 90° C. for 30 min. The wells are then washed extensively with distilled water.

EXAMPLE 5

Sequencing of Mismatch Regions

Immobilized DNAs prepared as described in Examples 1 and 2 above and subjected to mismatch recognition and cleavage (as described in Examples 3 or 4 above or by other methods) are incubated with a single-stranded oligonucleotide having the sequence 5'-CAGTAGTACAACCTGACCCTTTTGGGACCGC-3' [SEQ ID NO:1] under conditions in which efficient ligation of the oligonucleotide to free 5' ends is achieved. The oligonucleotide and immobilized DNA are combined in a solution containing 50 mM Tris HCl, pH 7.5, 10 mM MgCl₂, 20 mM dithiothreitol, 1 mM ATP, and 100 µg/ml bovine serum albumin, after which RNA ligase (Pharmacia Biotech,

the disease appears to be an autosomal recessive syndrome, DNA samples are obtained from those individuals presumptively heterozygous for the disease gene.

All DNA samples are subjected to mismatch analysis by hybridization to wild-type DNA as described in Example 2 above. The hybrids are then treated with T4 endonuclease 7 as described in Example 3 above. Finally, an oligonucleotide having the sequence 5'-CAGTAGTACAACCTGACCCTTTTGGGACCGC-3' [SEQ ID NO:1] is ligated to the cleaved hybrids using RNA ligase, and the products are subjected to enzymatic DNA sequencing as described in Example 5 above.

The sequences obtained from unaffected, affected, and presumptively heterozygous family members are compared with each other and with available sequence databases, using, for example, Sequencer (Gene Codes, Ann Arbor, Mich.) and Assembly Lign (Kodak, New Haven, Conn.) The sequences also serve as the basis for design of oligonucleotide probes, which are chemically synthesized and used to probe human genomic DNA libraries.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i i i) NUMBER OF SEQUENCES: 1

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: Adec = "synthetic oligonucleotide"

(i i i) HYPOTHETICAL: NO

(i v) ANTI-SENSE: NO

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CAGTAGTACA ACTGACCCTT TTGGGACCGC

3 0

Uppsala, Sweden) is added to the solution to achieve a final enzyme concentration of 0.1–5.0 U/ml. The reaction is allowed to proceed at 37° C. for 15 min. Following the ligation reaction, the solution is removed, and the wells are washed with distilled water.

DNA sequencing is then performed using the Sanger method (Sanger et al., *Proc. Natl. Acad. Sci. U.S.A.* 74:5463, 1977).

EXAMPLE 6

Positional Cloning of a Disease-causing Gene

The experiments described below are performed to rapidly localize and sequence a genomic region corresponding to a disease-causing gene.

A multiplex family in which a genetic disease is expressed is identified using standard clinical indicators. DNA samples are obtained from affected and unaffected individuals as described in Example 1 above; if by patterns of transmission

What is claimed is:

1. A method for identifying one or more genetic alterations in a target sequence present in a DNA sample, which comprises:

- a) immobilizing a first DNA sample, said first DNA having a 5' end and a 3' end on a solid support under conditions such that said 5' end is bound to said support and said 3' end is unbound;
- b) hybridizing said immobilized sample with a second DNA having a 5' end and a 3' end wherein said second DNA does not contain the alteration(s), to form heteroduplex DNA containing a mismatch region at the site of an alteration(s);
- c) cleaving one or both strands of said heteroduplex adjacent to said mismatch region to form a gap at or in the vicinity of said alteration;
- d) subjecting said cleaved heteroduplex to conditions of denaturation to dissociate said second DNA and cleaved first DNA 3' to the site of cleavage from immobilized remaining first DNA;

- c) removing DNA strands cleaved in step c and dissociated in step d from said immobilized remaining first DNA;
 - f) ligating a single-stranded oligonucleotide primer of known sequence to the unbound end of said immobilized remaining first DNA to form a ligation product;
 - (g) treating said ligation product with a DNA polymerase and an oligonucleotide complementary to said primer of known sequence in the presence of dideoxynucleotides or four nucleotide triphosphates and determining the nucleotide sequence adjacent to the ligated primer sequence; and
 - h) comparing said nucleotide sequence with a predetermined cognate wild-type sequence to identify said genetic alteration(s).
2. The method of claim 1, wherein the alterations are selected from the group consisting of additions, deletions, and substitutions of one or more nucleotides and combinations thereof.
3. The method of claim 1 further comprising blocking unbound ends on said heteroduplex DNA prior to the cleaving step.
4. The method of claim 3, wherein the blocking step comprises a method selected from the group consisting of removal of 5' phosphate groups, homopolymeric tailing of 3' ends with dideoxynucleotides, and ligation of modified double-stranded oligonucleotides.
5. The method of claim 1, wherein said target sequence is amplified prior to the immobilizing step.
6. The method of claim 1, wherein the solid support is selected from the group consisting of nitrocellulose filter, nylon filter, glass beads, and plastic.
7. The method of claim 1, wherein said cleaving step comprises exposing said heteroduplex DNA to one or more mismatch repair proteins under conditions appropriate for mismatch recognition and cleavage.
8. The method of claim 7, wherein the one or more mismatch repair proteins are selected from the group consisting of *Escherichia coli* proteins MutY, MutS, MutL, MutH, and combinations thereof, or functional homologues thereof.
9. The method of claim 8, wherein the functional homologues are derived from species selected from the group consisting of *Salmonella typhimurium*, *Streptococcus pneumoniae*, *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, mouse and human.
10. The method of claim 1, wherein said cleaving step comprises exposing said heteroduplex DNA to a mixture of nucleotide excision repair proteins under conditions appropriate for mismatch recognition and cleavage.
11. The method of claim 10, wherein the mixture comprises *E. coli* proteins UvrA, UvrB, and UvrC, or functional homologues thereof.
12. The method of claim 11, wherein the functional homologues are derived from species selected from the group consisting of *Saccharomyces cerevisiae* and human.
13. The method of claim 1, wherein said cleaving step comprises exposing said heteroduplex DNA to one or more resolvase proteins under conditions appropriate for mismatch recognition and cleavage.
14. The method of claim 13, wherein the resolvases are selected from the group consisting of bacteriophage T4 Endonuclease VII and bacteriophage T7 endonuclease I.
15. The method of claim 1, wherein said cleaving step comprises the steps of:
- (i) exposing said heteroduplex DNA to one or more chemical reagents under conditions appropriate for mismatch recognition and modification; and

- (ii) contacting recognized and modified heteroduplex DNA with one or more reagents to selectively cleave one strand in the vicinity of the modification.
16. The method of claim 15, wherein the chemical reagent is selected from the group consisting of hydroxylamine and osmium tetroxide.
17. The method of claim 1, wherein the single-stranded oligonucleotide primer is from about 15 to about 35 nucleotides.
18. The method of claim 1, wherein the ligating step is performed in the presence of RNA ligase.
19. The method of claim 1, wherein the determining step is performed by enzymatic DNA sequencing.
20. The method of claim 1, wherein the determining step is performed by hybridization to oligonucleotide arrays.
21. A method for identifying one or more genetic alterations in a target sequence present in a genomic DNA sample, which comprises:
- a) immobilizing a first DNA sample, said first DNA having a 5' end and a 3' end on a solid support under conditions such that said 5' end is bound to said support and said 3' end is unbound;
 - b) hybridizing said immobilized DNA sample with a second DNA sample, said second DNA having a 5' end and a 3' end, and wherein said second sample does not contain the alteration(s), to form heteroduplex DNA containing a mismatch region at the site of an alteration (s);
 - c) treating said heteroduplex with terminal transferase in the presence of a dideoxynucleotide to block unbound ends thereof;
 - d) contacting said heteroduplex with bacteriophage T4 endonuclease 7 to cleave one or both strands of said heteroduplex adjacent to said mismatch region to form a gap at or in the vicinity of said alteration;
 - e) subjecting said cleaved heteroduplex to conditions of denaturation to dissociate said second DNA and cleaved first DNA 3' to the site of cleavage from immobilized remaining first DNA;
 - f) removing DNA strands cleaved in step d and dissociated in step (e) from said immobilized remaining first DNA;
 - g) ligating a single-stranded oligonucleotide primer having the sequence 5'-CAGTAGTACAACCTGACCCCTTTTGGGACCGC-3' (SEQ ID NO:1) to the unbound end of immobilized remaining first DNA to form a ligation product;
 - (h) treating said ligation product with a DNA polymerase and an oligonucleotide complementary to said primer of known sequence in the presence of dideoxynucleotides or four nucleotide triphosphates and determining the nucleotide sequence adjacent to ligated primer sequence; and
 - i) comparing said nucleotide sequence with a predetermined cognate wild-type sequence to identify said alteration(s).
22. A method for identification of one or more mutation(s) in a DNA, which comprises:
- a) immobilizing one or more first DNA samples, said first DNA having a respective 5' end and a respective 3' end, on a solid support under conditions such that said 5' end is bound to said support and said 3' end is unbound;
 - b) hybridizing said immobilized sample(s) with a second DNA sample, said second DNA having a respective 5' end and a respective 3' end, and wherein said second

- sample does not contain the mutation(s), to form heteroduplex DNA containing a mismatch region at the site of a mutation;
- c) chemically blocking unbound ends on said heteroduplex DNA;
 - d) treating said heteroduplex DNA so that one or both strands are cleaved within or adjacent to said mismatch region to form a gap at or in the vicinity of said alteration;
 - e) subjecting said cleaved heteroduplex to conditions of denaturation to dissociate said second DNA and cleaved first DNA 3' to the site of cleavage from immobilized remaining first DNA;
 - f) removing DNA strands cleaved in step (d) and dissociated in step (e) from immobilized remaining first DNA;
 - g) ligating a single-stranded oligonucleotide primer of known sequence to the unbound end of said immobilized remaining first DNA to form a ligation product;
 - h) treating said ligation product with a DNA polymerase and an oligonucleotide complementary to said primer of known sequence in the presence of dideoxynucleotides or four nucleotide triphosphates and determining the nucleotide sequence adjacent to ligated primer sequence; and
 - i) comparing said nucleotide sequence with one or more predetermined cognate wild-type sequences to identify said mutation(s).
23. A method for multiplex identification of one or more mutations in a DNA, the method comprising:
- a) obtaining one or more first DNA samples, said DNA having a respective 5' end and a respective 3' end;
 - b) amplifying one or more target sequences in each of said samples;
 - c) immobilizing said amplified sequences on a solid support under conditions such that said 5' end is bound to said support and said 3' end is unbound;
 - d) hybridizing said immobilized sample(s) with a second DNA sample, said second DNA having a respective 5' end and a respective 3' end, and wherein said second sample does not contain the mutation(s), to form heteroduplex DNA containing a mismatch region at the site of a mutation;
 - e) chemically blocking unbound ends on said heteroduplex DNA;
 - f) treating said heteroduplex DNA so that one or both strands are cleaved within or adjacent to said mismatch region to form a gap at or in the vicinity of said mutation;
 - g) subjecting said cleaved heteroduplex to conditions of denaturation to dissociate said second DNA and cleaved first DNA 3' to site of cleavage from immobilized remaining first DNA;
 - h) removing DNA strands cleaved in step (f) and dissociated in step (g) from said immobilized remaining first DNA;
 - i) ligating a single-stranded oligonucleotide primer of known sequence to the unbound end of said immobilized remaining first DNA to form a ligation product;
 - j) treating said ligation product with a DNA polymerase and an oligonucleotide complementary to said primer of known sequence in the presence of dideoxynucleotides or four nucleotide triphosphates and determining the nucleotide sequence adjacent to ligated primer sequence; and

- k) comparing said nucleotide sequence with one or more predetermined cognate wild-type sequences to identify said mutation(s).
24. The method of claim 1 wherein the DNA samples are denatured prior to hybridization.
25. The method of claim 21 wherein the DNA samples are denatured prior to hybridization.
26. The method of claim 22 wherein the DNA samples are denatured prior to hybridization.
27. The method of claim 23 wherein the DNA samples are denatured prior to hybridization.
28. A method for positional cloning of a gene of interest, the method comprising:
- a) immobilizing a first DNA sample from an individual displaying a given phenotype, said first DNA having a 5' end and a 3' end on a solid support under conditions such that said 5' end is bound to said support and said 3' end unbound;
 - b) hybridizing said immobilized sample with a second DNA sample, said second DNA having a 5' end and a 3' end, and wherein said second DNA sample is from one or more individual(s) not displaying said phenotype to form heteroduplex DNA containing a mismatch region at the site of a genetic alteration;
 - c) cleaving one or both strands of said heteroduplex DNA to form a gap at or in the vicinity of said alteration;
 - d) subjecting said cleaved heteroduplex to conditions of denaturation to dissociate said second DNA from said first DNA;
 - e) removing DNA strands cleaved in step (c) and dissociated in step (d) from said first DNA;
 - f) ligating a single-stranded oligonucleotide primer of known sequence to the 3' end of first cleaved DNA to form a ligation product;
 - g) treating said ligation product with a DNA polymerase and an oligonucleotide complementary to said primer of known sequence in the presence of dideoxynucleotides or four nucleotide triphosphates and determining the nucleotide sequence adjacent to ligated primer sequence;
 - h) preparing a synthetic oligonucleotide comprising all or part of said determined nucleotide sequence; and
 - i) identifying a DNA clone that hybridizes to said oligonucleotide.
29. The method of claim 28 which comprises chemically blocking free terminal ends of said heteroduplex prior to said cleaving steps.
30. The method of claim 28, wherein the genetic alterations are selected from the group consisting of additions, deletions, and substitutions of one or more nucleotides and combinations thereof.
31. The method of claim 28, wherein the cleaving step comprises exposing the heteroduplex DNA to a mixture of mismatch repair proteins under conditions appropriate for mismatch recognition and cleavage.
32. The method of claim 31, wherein the mismatch repair proteins are selected from the group consisting of *Escherichia coli* proteins MutY, MutS, MutL, MutH, and combinations thereof, or functional homologues thereof.
33. The method of claim 32, wherein the functional homologues are from species selected from the group consisting of *Salmonella typhimurium*, *Streptococcus pneumoniae*, *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, mouse and human.
34. The method of claim 28, wherein the cleaving step comprises exposing the heteroduplex DNA to a mixture of

nucleotide excision repair proteins under conditions appropriate for mismatch recognition and cleavage.

35. The method of claim 34, wherein the mixture comprises *Escherichia coli* proteins UvrA, UvrB, and UvrC, or functional homologues thereof.

36. The method of claim 35, wherein the functional homologues are from species selected from the group consisting of *Saccharomyces cerevisiae* and human.

37. The method of claim 28, wherein the cleaving step comprises exposing the heteroduplex DNA to one or more resolvase proteins under conditions appropriate for mismatch recognition and cleavage.

38. The method of claim 37, wherein the resolvases are selected from the group consisting of bacteriophage T4 Endonuclease VII and bacteriophage T7 endonuclease I.

39. The method of claim 28, wherein the cleaving step comprises the steps of:

- (i) exposing the heteroduplex to one or more chemical reagents under conditions appropriate for mismatch recognition and modification; and
- (ii) contacting said recognized and modified heteroduplex DNA with one or more reagents to selectively cleave one strand in the vicinity of the alteration.

40. The method of claim 39, wherein the chemical reagent is selected from the group consisting of hydroxylamine and osmium tetroxide.

41. The method of claim 28, wherein the single-stranded oligonucleotide primer is from about 15 to about 35 nucleotides.

42. The method of claim 28, wherein the ligating step is performed in the presence of RNA ligase.

43. The method of claim 28, wherein the determining step is performed by enzymatic DNA sequencing.

44. The method of claim 28, wherein the determining step is performed by hybridization to oligonucleotide arrays.

45. The method of claim 28, wherein the identifying step is achieved using a method selected from the group consisting of colony hybridization, identification of tissue-specific expression, reverse transcription-amplification of mRNA, and screening of an affected population for genotype/phenotype association.

46. The method of claim 28, wherein the DNA samples are denatured prior to hybridization.

47. The method of claim 28, wherein the first DNA is immobilized on a solid support under conditions such that said 5' end is bound to said support and said 3' end is unbound.

* * * * *